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PHYSICS CONTRIBUTION
ADAPTIVE RADIOTHERAPY PLANNING ON DECREASING GROSS TUMOR
VOLUMES AS SEEN ON MEGAVOLTAGE COMPUTED TOMOGRAPHY IMAGES
CURTIS WOODFORD,* SLAV YARTSEV, PH.D.,* A. RASHID DAR, M.D.,*y GLENN BAUMAN, M.D.,*y
AND JAKE VAN DYK, M.SC.*y
*London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada; and
yThe University of Western Ontario, London, Ontario, Canada
Purpose: To evaluate gross tumor volume (GTV) changes for patients with non–small-cell lung cancer by using
daily megavoltage (MV) computed tomography (CT) studies acquired before each treatment fraction on helical
tomotherapy and to relate the potential benefit of adaptive image-guided radiotherapy to changes in GTV.
Methods and Materials: Seventeen patients were prescribed 30 fractions of radiotherapy on helical tomotherapy
for non–small-cell lung cancer at London Regional Cancer Program from Dec 2005 to March 2007. The GTV was
contoured on the daily MVCT studies of each patient. Adapted plans were created using merged MVCT–kilovolt-
age CT image sets to investigate the advantages of replanning for patients with differing GTV regression
characteristics.
Results: Average GTV change observed over 30 fractions was 38%, ranging from 12 to 87%. No significant
correlation was observed between GTV change and patient’s physical or tumor features. Patterns of GTV changes
in the 17 patients could be divided broadly into three groups with distinctive potential for benefit from adaptive
planning.
Conclusions: Changes in GTV are difficult to predict quantitatively based on patient or tumor characteristics. If
changes occur, there are points in time during the treatment course when it may be appropriate to adapt the plan to
improve sparing of normal tissues. If GTV decreases by greater than 30% at any point in the first 20 fractions of
treatment, adaptive planning is appropriate to further improve the therapeutic ratio.  2007 Elsevier Inc.
Helical tomotherapy, Lung cancer, Plan reoptimization, Adaptive planning.
INTRODUCTION
The megavoltage (MV) computed tomography (CT) acquisi-
tion capability of helical tomotherapy has proved very effec-
tive for pretreatment patient positioning to decrease setup
errors (1, 2). The MVCT image sets depict the patient’s anat-
omy with image contrast and resolution that is slightly infe-
rior to a kilovoltage CT (kVCT) study, but has enough
soft-tissue contrast to reliably contour organs or lesions in
many areas of the body (3, 4). In particular, peripheral-lung
tumors can be easily detected and delineated on MVCT
image sets. However, significant uncertainty in target delin-
eation may be associated with tumors partially abutting or
primarily contained in the mediastinum (5, 6). If treatment
for patients with non–small-cell lung cancer (NSCLC) on
helical tomotherapy involves regular MVCT imaging, the
gross tumor volume (GTV) response to radiotherapy can
potentially be assessed on a daily basis.
Tumor control predictions based on pretreatment measure-
ments are well studied, and most investigators used the crite-
rion of tumor size measured by largest tumor dimension,
bidimensional product, or tumor volume for a local control
predictor. Usefulness of tumor size/volume as an overall
prognostic factor for survival is still under discussion (7–
9). Correlation of pretreatment tumor size with local control
suggests that such tumor characteristics as size could possi-
bly be used to anticipate the amount of GTV regression dur-
ing a course of treatment. Generally, NSCLC tumor response
to radiotherapy is believed to be a slow process because
tumors reach their maximum response (minimum volume)
an average of 11 months after radiotherapy completion (9).
Kupelian et al. (10) and Siker et al. (11) used measurements
of tumor volume on serial MVCT image sets generated by
helical tomotherapy to document interfractional radiation
responses during a shorter period, whereas Ramsey et al.
(12) focused on adaptive dosimetric planning as tumor
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volume changes. Others used multiple kVCT scans to evalu-
ate tumor volume changes during radiotherapy (13–16) or
portal images to monitor tumor position, size, and movement
(17). All these investigators observed tumor volume shrink-
age to varying degrees during the course of fractionated treat-
ment, suggesting tumor volume changes during shorter
periods may be clinically relevant. The aim of this report is
to evaluate GTV changes in 17 patients treated for NSCLC
on helical tomotherapy, characterize GTV variation, and
model the potential benefit of adaptive planning during
a course of fractionated radiotherapy.
METHODS AND MATERIALS
Seventeen patients were treated for NSCLC on the Hi-Art helical
tomotherapy (TomoTherapy, Inc., Madison, WI) unit at the London
Regional Cancer Program, Ontario, Canada, from December 2005 to
March 2007. All patients received cisplatin and vinorelbine as neo-
adjuvant chemotherapy, finishing treatment 4–6 weeks before the
start of radiotherapy. Chemotherapy is not expected to affect relative
GTV changes from radiotherapy in patients because all patients were
treated using the same regimen. The CT simulation and tomotherapy
treatment planning (Hi-ART, version 2.2.2) occurred approximately
3 weeks before starting treatment, with delivery quality assurance
performed to ensure proper dose distributions and absolute dose de-
livery. One initial mock treatment that included an MVCT study was
performed for each patient, after which they began treatment with
daily MVCT acquisitions for setup verification. A prescription
dose of 60–64 Gy in 2 Gy/fraction was used for patients in this study,
all of whom had locally advanced (Stage $ IIIA) disease. Elective
nodal radiation was included for some patients, with doses of 50 or
60 Gy delivered to adjacent radiographically uninvolved nodal re-
gions. The MVCT scans on the Hi-Art system were acquired with
photon beam energy of 3.5 MV, field of view of 40 cm, fan beam
width of 5 mm at the isocenter, and pitch factor of 2.4 for coarse
(6-mm) slices (3). The reconstruction matrix was 512  512 in the
axial plane, yielding a 0.78  0.78  6-mm3 voxel size. For this
patient population, Planned Adaptive (TomoTherapy, Inc.) soft-
ware was not available at the time of treatment. For this reason, an
additional kVCT study was performed for 6 patients to construct
an adapted plan at the request of the treating radiation oncologist
for patients with local anatomy changes deemed clinically significant
on serial MVCTs during the actual treatment course.
For this report, GTV volume changes were calculated retrospec-
tively based on the serial MVCTs obtained daily during treatment.
For calculation of GTV changes during the course of treatment,
GTV was contoured after transferring the daily MVCT studies for
each patient from the helical tomotherapy unit to a treatment planning
system (either Pinnacle3 version 8.0d; Philips, Fitchburg, WI, or On-
centra Treatment Planning, version 1.3.1.13; Nucletron, Veenendaal,
The Netherlands). The MVCT images were contoured with a win-
dow/level setting of 1600/300 for tumor bounded by parenchyma
and 400/800 for tumor abutting the mediastinum. The kVCT studies
for each patient were available to provide guidance to the investigator
(C.W.) who did the MVCT contouring. Involved nodes were ex-
cluded from the GTV; only primary tumor volume was measured
for the purpose of calculating response in this report.
The MVCT images generated by using helical tomotherapy can
also be used to create adapted plans when significant changes in
the patient’s GTV are observed as treatment progresses. In our
study, Planned Adaptive software was used to create merged images
for 3 patients in which the 40-cm field of view of the pretreatment
MVCT replaced the corresponding section of the full planning
kVCT. The registration values used to position patients for treatment
were also used to adjust the position of the MVCT study relative to
the kVCT study when creating the merged kVCT-MVCT images.
These registration values were determined by using semiautomated
registration software on the helical tomotherapy treatment console.
The 6-mm slices of the MVCT studies were changed to 3-mm slices
by interpolation to correspond with the slice spacing of the kVCT
studies. The original contours used for planning on the kVCT stud-
ies were overlaid on the merged images, and they were altered by the
investigators to reflect changes in target and lung volumes based on
the merged kVCT-MVCT images. The only structures that typically
required modification on the merged images were the lungs (to ac-
count for changes in atelectasis or pleural effusion) and the GTVs
and planning target volumes (PTVs; to account for target volume
changes). A three-dimensional (3D) margin of 12 mm (correspond-
ing to the original margins for the initial plans) was added to the
GTVs to generate the PTVs. Although 4D-CT was not performed
on these patients to quantify respiratory motion, Schwarz et al.
(18) recommended a 10-mm GTV-PTV margin for patients with
breathing amplitudes of up to 10 mm undergoing intensity-modu-
lated radiotherapy. Because GTV-PTV margins are anatomy and pa-
tient specific, a margin of 12 mm was chosen to ensure target
coverage beyond that provided by a 10-mm margin.
The merged images created with the MVCT scans from 3 patients
were transferred to the TomoTherapy planning station to create
adapted plans. Using a merged image for planning radiation delivery
assumes the patient’s anatomy outside the region of interest covered
by the MVCT has not changed since planning and that the dose
calculation using merged images is accurate.
At the London Regional Cancer Program, we have planned and
treated prostate cancer patients with hip prostheses using merged
images. Accuracy of dose calculation with merged image plans pre-
viously was confirmed for sites in the head and neck, lung, and pros-
tate by creating a merged image plan and testing the delivery of the
plan on tomotherapy by using three ion chamber measurements and
one film exposure in a cylindrical phantom as quality assurance.
Three patients were investigated with this adaptive planning
method using merged images to find out whether plan improve-
ments can be significant for the patient and distinguish between clin-
ically insignificant or significant anatomy changes based on their
adaptive planning potential. To evaluate the quality of the adapted
plans, the cumulative doses to the PTV and lungs are reported.
The cumulative dose,Dc, is defined as the total dose delivered to a re-
gion of interest during the course of treatment. When using multiple
adapted plans, where i is the plan number (i = 1, 2, 3,.), di is the
planned dose to the region of interest, ni is the number of fractions







Cumulative doses were calculated for the 3 patients based on the
adapted plans using merged images as the planning image set. The
adapted plans (APs) are referred to by the fraction number of the
MVCT used to create the merged image, so AP10 is an adapted
plan created using the MVCT from the tenth fraction of treatment.
Doses to 99% and 1% of the PTV, along with mean lung dose
(MLD) and volume of lung tissue that receives more than 20 Gy
(V20), were compared (19, 20).
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RESULTS
As listed in Table 1, average initial GTV for the 17 patients
was 127 115 (SD) cm3. Average total GTV change observed
was38% 20%, ranging from a 12–87% decrease in tumor
volume. Mean volume change per day was0.79% 0.36%,
with a range of 0.24–1.65% decrease per day. There was no
correlation of either rate of volume change or total volume
change with initial tumor volume or of volume changes with
radiotherapy treatment time. Histologic characteristics and
staging did not affect rate or overall tumor volume decrease ac-
cording to our data. Multiple regression analysis was carried
out for such patient characteristics as PTV-lung overlap, ipsi-
lateral-contralateral lung ratio (21), tumor density, and tumor
size, but no significant correlation with tumor regression
among any combination of these was found.
Three general patterns of tumor volume changes were ob-
served in these 17 patients. Group A (5 patients) experienced
an initial period of small tumor volume change, followed by
a sharp decrease in tumor volume and subsequent plateau, as
shown in Fig. 1. Group B (8 patients) had a more gradual lin-
early decreasing tumor volume, as shown in Fig. 2. Group C
(4 patients) experienced variable volume changes with no
clear trend toward a decrease in volume (Fig. 3).
Each of these three groups offers different opportunities
for adaptive radiotherapy planning. There is a trade-off be-
tween cost, timing, and number of adaptive plans one may
devise. For example, Table 2 lists cumulative doses using
adapted plans at various points in the treatment of 1 patient
in Group A (Patient 1; Fig. 1). Creating more adapted plans
will increase resource utilization, but potentially, V20 and
MLD will improve. If the adapted plan is created near the
end of treatment, the overall cumulative dose will be affected
very little by the improved plan because it will be used for
treatment over fewer fractions. The rate and extent of GTV
reduction is variable and patient dependent which determines
the optimal timing and potential impact of replanning. For
example, Patient 1 had a dramatically high response in a short
time and thus was well positioned to benefit from replanning.
The decrease in MLD and V20 to Patient 1 as a result of adap-
tive planning and the time at which the plan was made may
not be applicable to the other patients in Group A, who had
less dramatic and more delayed GTV changes.
Table 3 lists cumulative doses using adapted plans for 2 pa-
tients (Patients 6 and 10) from Group B. Patient 6 had a higher
MLD and V20 than Patient 10 for the initial kVCT plan. The
adapted plan for Patient 6 was made after a 31% GTV de-
crease during 25 days and 16 fractions, and for Patient 10, af-
ter a 27% GTV decrease during 32 days and 21 fractions. For
similar tumor volume changes contoured on MVCT studies,
the adapted plan was capable of improving the treatment of
Patient 6, who had higher lung doses compared with the treat-
ment of Patient 10, who had lower lung doses. Group C offers
little benefit for adapted plans because of the delayed tumor
response, which usually results in a less than 25% volume
decrease late in the treatment course. Although this is the
case in this study, if anatomic changes had occurred because of
atelectatic regression or change in tumor shape, adaptive plan-
ning may have been appropriate for Group C patients.
DISCUSSION
The GTV changes observed on helical tomotherapy by
Kupelian et al. (10) and Siker et al. (11) are compared with


















1 85/M A LC IIIA 2 60/30 53 30 202 87 1.65
2 68/F B A IIIB 2 60/30 65 33 100 71 1.09
3 67/M B S IIIB 1 60/30 54 29 51 39 0.72
4 76/M B S IIIA 1 60/30 44 30 156 52 1.18
5 60/M A A IIIA 2 60/30 49 31 115 22 0.45
6 76/M B LC IIIB 1 60/30 49 28 33 57 1.16
7 70/M B A IIIB 1 60/30 46 30 174 38 0.82
8 45/F C A IV 1 50/25 42 25 171 18 0.73
9 60/M C S IV 1 60/30 44 29 3 41 0.92
10 76/M B S IIIB 1 63/30 47 31 41 42 0.89
11 71/M A A IIIA 2 64/32 52 30 250 44 0.86
12 70/M B S IIIA 1 60/30 44 30 132 32 0.67
13 70/M A NSC IIIA 2 60/30 48 30 108 41 0.80
14 71/M C NSC IIIA 1 60/30 51 29 38 15 0.34
15 77/M A NSC IIIA 1 60/30 45 31 485 20 0.43
16 77/F B A IIIB 2 50/25 49 25 65 12 0.24
17 76/F C S IIIA 1 62/31 49 31 36 23 0.45
Mean 70 48 30 127 38 0.79
SD 9 8 2 115 20 0.36
Abbreviations: LC = large cell carcinoma; A = adenocarcinoma; S = squamous cell carcinoma; NSC = non–small cell; MVCT = megavoltage
computed tomography; GTV = gross tumor volume.
* Dose prescribed to 95% of the planning target volume.
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results of our study in Table 4, using criteria of Siker et al.
(11) for complete, partial, and marginal responses or stable
disease. The GTV changes noted by Kupelian et al. (10)
are greater than the results reported here (22). However,
our study shows greater marginal response and less stable
disease than the study by Siker et al. (11). In part, this is be-
cause complete data from Siker et al. (11) include a mixture
of treatment strategies: patients treated palliatively and with
extracranial stereotactic radioablation. Our study included
only patients treated with conventional definitive treatment
(see Table 1), and when the palliative and extracranial stereo-
tactic radioablation patient groups are excluded from the data
from Siker et al. (11), there is better agreement with our study
(see Siker* column in Table 4). Total doses in this study are
Fig. 1. Gross tumor volume changes for patients in Group A. Circles show days the adapted plans were used for Patients 1,
5, 11, and 13.
Fig. 2. Gross tumor volume changes for patients in Group B. Circles show days the adapted plans were used for Patients 2 and 16.
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similar to those of Siker et al. (11), but the patients treated
radically in the study by Siker et al. (11) received prescrip-
tions based on a hypofractionation treatment that lasted 5
weeks, whereas the patients treated radically in our study
were treated during a mean time of 7 weeks, ranging from
3.5–9 weeks. The higher response rates in our study may
be a result of the longer treatment periods given that tumor
response to radiotherapy increases with time (to a point).
As noted by Siker et al. (11), their response rate observed
during the course of treatment could be higher had they not
used a dose-per-fraction escalation strategy that resulted in
a shorter total treatment time.
Repeated adapted plans using an additional kVCT study
were used for treatment of 6 patients (see Table 1). The deci-
sion to replan was made by the treating radiation oncologist
based on the extent of change in the patient’s internal anat-
omy as a result of GTV change. The primary advantage for
replanning lies in greater normal tissue sparing without detri-
mental effects on PTV dose coverage. We showed that this
aim can be met by using merged MVCT and kVCT studies
with some structures previously contoured on the planning
kVCT. The adapted plan data listed in Tables 2 and 3 show
that adaptive planning before the 22nd fraction in the treat-
ment is more beneficial, and inferior plans can benefit more
from adaptive planning than very good plans. Also, adaptive
planning can yield significant improvements in cumulative
doses to organs at risk (OARs) after a GTV decrease of ap-
proximately 30% or more, provided that decrease occurs at
approximately the first 15–20 fractions of treatment, which
happened in 40% of the patients in the study. The pattern
of regression is a main end point in this study because it
determines the optimal point for adaptive planning. If the
patient belongs to Group A, an adapted plan may be
beneficial at the end of the high rate tumor regression to im-
prove the therapeutic ratio during treatment in the plateau re-
gion. Patients in Group B should be considered for adapted
plans only if their tumor volume decreases by more than
30% in the first 22 fractions, whereas adaptive planning
benefits for patients in Group C will not be significant in
most cases.
The 30% threshold mentioned is not intended to be a con-
crete principle, but is useful as a criterion to identify or ‘‘flag’’
patients for adaptive planning evaluation. GTV is an informa-
tive parameter in this respect and was chosen as a criterion
Fig. 3. Gross tumor volume changes for patients in Group C.
Table 2. Cumulative doses for adapted plan combinations for Patient 1 from Group A
No AP AP10 AP15 AP10 + AP15 AP22 AP10 + AP22 AP15 + AP22 AP10 + AP15 + AP22
PTV D1 (Gy) 62.6 62.2 63.1 63.0 62.3 62.0 62.5 62.4
PTV D99 (Gy) 58.4 58.3 57.8 57.7 58.6 58.5 58.3 58.2
MLD (Gy) 16.3 15.4 14.9 14.7 14.7 14.2 14.1 13.9
V20 (Gy) 27.7 26.6 24.9 24.6 25.6 25.0 24.3 24.0
Abbreviations: APx = adapted plan after x fractions; APx + APy = adapted plan after x fractions and after y fractions; Dx = dose planned to x%
of the PTV; MLD = mean lung dose; PTV = planning target volume; V20 = volume of lung receiving greater than 20 Gy.
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because it is easy to evaluate radiologically. The possibility
of benefiting from adaptive planning is suggested when a
patient reaches or crosses this threshold, but actual benefits
also rely on such variables as the existence of elective nodal
irradiation or proximity of organs at risk. In cases in which
organs at risk are dose limiting, it would be apt to evaluate
the adaptive planning potential sooner and more often.
When a patient’s GTV does not cross the suggested threshold
and is not accompanied by significant anatomy changes, it is
not necessary to use resources creating and evaluating the
need for adapted plans. Implementation of such a strategy
does not rely on the availability of onboard CT imaging. A
repeated CT simulation during the third or fourth week of
treatment could accomplish the goal of identifying patients
who could benefit from replanning.
Haasbeek et al. (16) showed that adaptive planning for pa-
tients with Stage I NSCLC undergoing stereotactic radiother-
apy was not necessary based on repeated 4D CTs after 2–12
days after the first stereotactic fraction. Our study covers
a longer period and the patients have more advanced disease,
which is likely why our conclusions about adaptive planning
differ. Siebert et al. (23) were successful in their efforts to
predict GTV change in a group of 19 patients treated with
helical tomotherapy. Their empirical model was based on a
locally weighted regression learning algorithm. In our patient
set, we could not measure any tumor or patient characteristics
or combination thereof that correlated with GTV change.
Deformable registration was not used in this study to cal-
culate cumulative doses to OARs and target volumes, but
could be a valuable extension. Were this technique used,
more specific definition of doses to all structures could be de-
termined with reliable dose–volume histograms. The biggest
advantage it could endow is the ability to create adapted plans
that compensate for underdosage or overdosage of targets or
OARs. In addition to GTV change, more criteria for adapted
planning potential could involve patients who experienced
a variation from the planned dose greater than a threshold
value.
Although GTV changes are caused mostly by cancer reduc-
tion, the observations reported here may be affected by other
factors, such as breathing or atelectatic changes. Breathing
patterns can change during the course of treatment (24). The
apparent volume visible on the MVCT will change if breath-
ing amplitude changes because MVCT acquisition is similar
to a slow CT scan. The GTV motion creates artifacts that in-
crease the contouring uncertainty and result in an image that is
not exactly reflective of the actual tumor position or size (25).
The GTVs alone may not completely reveal the response
to radiotherapy because neither kVCT nor MVCT imaging
techniques can reliably detect tumor composition. Although
tumors may not decrease much in volume, necrosis, nonma-
lignant tissue, and inflammation could replace malignant tis-
sue, but may be indistinguishable by using CT (26). It also
was shown that tumor composition was heterogeneous and
tumor volumes were not reflective of the amount of actively
replicating cancerous tissue (27). This result could explain
why Kupelian et al. (10) observed a more rapid decrease in
GTV for larger tumors, but unfortunately that result was
not reproduced in the present study or by Siker et al (11). It
also is not clear yet whether regressing tumors leave behind
nests of cells that should be treated further or whether smaller
fields still adequately encompass subclinical disease. Our hy-
pothesis is that if the gross tumor regresses, the microscopic
extension disappears proportionally, and reducing the PTV
would not result in decreased coverage of diseased tissue,
but this conjecture is unconfirmed to date. Microscopic
extension of NSCLC was quantified in postoperative speci-
mens, but studying its change during the course of radiother-
apy is impossible by using histologic techniques because the
tumor is surgically excised (28). Ideally, serial biologic-
based imaging acquired during a course of radiation would
be available to provide information in addition to the tissue
density change information available with CT studies. Unfor-
tunately, this adds to the logistic complexity of the replanning
process, even when using such existing biologic imaging
as positron emission tomography, but it is still an area worth
exploring.
CONCLUSION
We observed decreases in GTV in 17 patients with
NSCLC during the standard course of fractionated treatment
with helical tomotherapy. Significant improvement in cumu-
lative doses by using adapted plans can be made after tumor
volume decreases by greater than 30% within the first 20
treatment fractions. In 40% of patients in this study, GTV
Table 3. Cumulative doses for adapted plan combinations
for Patients 6 and 10 from Group B











PTV D1 (Gy) 61.9 62.3 0.6 65.8 65.7 0.2
PTV D99 (Gy) 59.4 59.2 0.4 61.9 62.0 0.1
MLD (Gy) 15.1 14.5 4.1 10.3 10.0 2.4
V20 (Gy) 26.1 24.2 7.4 15.1 14.7 3.2
Abbreviations: APx = adapted plan after x fractions; Dx = dose
planned to x% of the PTV; MLD = mean lung dose; PTV = planning
target volume; V20 = volume of lung receiving greater than 20 Gy.




volume (%) LRCP Kupelian Siker Siker*
Complete 100 0 0 0 0
Partial 65–99 12 80 12 18
Marginal 35–64 47 20 20 29
Stable
disease
0–34 41 0 68 53
Abbreviation: LRCP = London Regional Cancer Program.
* There are two different data sets from Siker.
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changes were of sufficient magnitude and occurred suffi-
ciently early in the treatment course that one could realisti-
cally anticipate that adapted radiotherapy would improve
the therapeutic ratio and clinical results. Continuation of
this study on a larger patient base will lead to the formulation
of guidelines regarding adaptive planning based on merged
image plans and to improved ability to identify patients
before treatment who may require later adapted planning.
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